Principal Financial Group Inc Cti Biopharma Corp Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$4.2 - $6.01 $9,853 - $14,099	2,346 Added 8.41%	30,244 $127,000
Q4 2022 Feb 09, 2023	BUY	$4.45 - $6.17 $26,246 - $36,390	5,898 Added 26.81%	27,898 $167,000
Q3 2022 Nov 09, 2022	BUY	$5.36 - $7.43 $24,420 - $33,851	4,556 Added 26.12%	22,000 $128,000
Q2 2022 Aug 10, 2022	BUY	$3.55 - $6.27 $61,926 - $109,373	17,444 New	17,444 $104,000
Q4 2018 Feb 14, 2019	SELL	$0.73 - $2.19 $7,909 - $23,728	-10,835 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.72 - $5.24 $18,636 - $56,775	10,835 New	10,835 $23,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.